New aminopropandiol derivatives as orally available and short-acting calcium-sensing receptor antagonists

Bioorganic and Medicinal Chemistry Letters

Volumn 20, Issue 12, 2010, Pages 3809-3813

  Shinagawa, Yuko ^a   Inoue, Teruhiko ^a   Hirata, Kazuyuki ^a   Katsushima, Takeo ^a   Nakagawa, Takashi ^a   Matsuo, Yushi ^a   Shindo, Masanori ^a   Hashimoto, Hiromasa ^a  

^a JAPAN TOBACCO INC   (Japan)

Author keywords

Antagonist; Calcilytics; Calcium sensing receptor; CaSR antagonist; Osteoporosis; PTH

Indexed keywords

2 CHLORO 6 [3 [1,1 DIMETHYL 2 (2 NAPHTHYL)ETHYLAMINO] 2 HYDROXYPROPOXY]BENZONITRILE; AMINOPROPANDIOL DERIVATIVE; ANABOLIC AGENT; CALCIUM SENSING RECEPTOR; PARATHYROID HORMONE; RECEPTOR BLOCKING AGENT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CHEMICAL MODIFICATION; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG STRUCTURE; DRUG SYNTHESIS; NONHUMAN; PARATHYROID HORMONE RELEASE; RAT; STRUCTURE ACTIVITY RELATION; X RAY DIFFRACTION;

ANIMALS; BIOLOGICAL AVAILABILITY; OSTEOPOROSIS; PARATHYROID HORMONE; PROPANOLAMINES; RATS; RECEPTORS, CALCIUM-SENSING; STRUCTURE-ACTIVITY RELATIONSHIP;

RATTUS;

EID: 77954218297     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2010.04.035     Document Type: Article

References (20)

1. Report of a WHO Scientific Group, Geneva, World Health Organization, 2003 (WHO Technical Report Series No.921). Available at http://whqlibdoc.who.int/ trs/WHO-TRS-921.pdf.
2. C. Deal Clin. Rev. Bone Miner. Metab. 3 2005 125
3. R.M. Neer, C.D. Arnaud, J.R. Zanchetta, R. Prince, G.A. Gaich, J.Y. Reginster, A.B. Hodsman, E.F. Eriksen, S. Ish-Shalom, H.K. Genant, O. Wang, and B.H. Mitlak N. Engl. J. Med. 344 2001 1434
4. E.M. Brown, and R.J. MacLeod Physiol. Rev. 81 2001 239
5. D.B. Kimmel, R.P. Bozzato, K.A. Kronis, T. Coble, D. Sindrey, P. Kwong, and R.R. Recker Endocrinology 132 1993 1577
6. W. Yang, Y. Wang, J.Y. Roberge, Z. Ma, Y. Liu, R.M. Lawrence, D.P. Rotella, R. Seethala, J.H.M. Feyen, and J.K. Dickson Jr. Bioorg. Med. Chem. Lett. 15 2005 1225
7. I. Shcherbakova, M.F. Balandrin, J. Fox, A. Ghatak, W.L. Heaton, and R.L. Conklin Bioorg. Med. Chem. Lett. 15 2005 1557
8. I. Shcherbakova, G. Huang, O.J. Geoffroy, S.K. Nair, K. Swierczek, M.F. Balandrin, J. Fox, W.L. Heaton, and R.L. Conklin Bioorg. Med. Chem. Lett. 15 2005 2537
9. A.V. Gavai, R.J. Vaz, A.B. Mikkilineni, J.Y. Roberge, Y. Liu, R.M. Lawrence, J.R. Corte, W. Yang, M. Bednarz, J.K. Dickson Jr., Z. Ma, R. Seethala, and J.H.M. Feyen Bioorg. Med. Chem. Lett. 15 2005 5478
10. R.W. Marquis, A.M. Lago, J.F. Callahan, R.E.L. Trout, M. Gowen, E.G. DelMar, B.C. Van Vegnan, S. Logan, S. Shimizu, J. Fox, E.F. Nemeth, Z. Yang, T. Roethke, B.R. Smith, K.W. Ward, J. Lee, R.M. Keenan, and P. Bhatnagar J. Med. Chem. 52 2009 3982
11. G. Balan, J. Bauman, S. Bhattacharya, M. Castrodad, D.R. Healy, M. Herr, P. Humphries, S. Jennings, A.S. Kalgutkar, B. Kapinos, B. Khot, K. Lazarra, M. Li, Y. Li, C. Neagu, R. Oliver, D.W. Piotrowski, D. Price, H. Qi, H.A. Simmons, J. Southers, L. Wei, Y. Zhang, and J.M. Paralkar Bioorg. Med. Chem. Lett. 19 2009 3328
12. Fitzpatrick, L. A.; Brennan, E.; Kumar, S.; Matheny, C.; Yi, B.; McLaughlin, M.; Phillips, J.; Skordos, L.; Ethgen, D. Women. ASBMR 30th Annual Meeting-FINAL-Abstract-Book 2008, 50, 1174.
13. Fukumoto, S.; Nakamura, T.; Nishizawa, Y.; Hayashi, M.; Matsumoto, T. J. Bone Miner. Res. 24. Available at http://www.asbmr.org/Meetings/AnnualMeeting/ AbstractDetail.aspx?aid=f7a434e5-ad26-4aa0-930d-5bca406c9317. Accessed October 10, 2009.
14. E.F. Nemeth, E.C. Delmar, W.L. Heaton, M.A. Miller, L.D. Lambert, R.L. Conklin, M. Gowen, J.G. Gleason, P.K. Bhatnagar, and J. Fox J. Pharm. Exp. Ther. 299 2001 323
15. M. Gowen, G.B. Stroup, R.A. Dodds, I.E. James, B.J. Votta, B.R. Smith, P.K. Bhatnagar, A.M. Lago, J.F. Callahan, E.G. Del Mar, M.A. Miller, E.F. Nemuth, and J. Fox J. Clin. Invest. 105 2000 1595
16. Shinagawa, Y.; Katsushima, T.; Nakagawa, T. U.S. Patent 6,916,956 B2, 2005.
17. The endogenous plasma PTH levels after oral administration of the compounds in Sprague-Dawley rats were measured using rat PTH 1-34 ELISA kit (Amersham) or rat PTH 1-84 ELISA kit (Immutopics). See Ref. 10 for the experimental details. We observed PTH 1-34 in the screening stage (Table 3) and PTH 1-84 in the time course study for compound (R,R)-31 (Fig. 2).
18. R: 12.4 min for 42, 13.6 min for 45).
19. T. Ohkuma, H. Ooka, S. Hashiguchi, T. Ikariya, and R. Noyori J. Am. Chem. Soc. 117 1995 2675
20. The data can be obtained from the Cambridge Crystallographic Data Centre (CCDC 770504).